Biomarkers-based personalized follow-up in chronic heart failure improves patient’s outcomes and reduces care associate cost
Heart failure (HF) is a major and growing medical and economic problem, with high prevalence and incidence rates worldwide.In an interventional study, A. Leon-Justel et al. (Spain) assessed the impact of a personalised follow-up procedure for Heart Failure (HF) on 192 patient’s outcomes and care associated cost, based on a clinical model of risk stratification and personalised management according to that risk.
The personalised follow-up led to important outcome benefits and resulted in cost savings, mainly due to the reduction of patient hospitalisation readmissions and a significant reduction of care-associated costs.
The authors suggest that “greater attention should be given to this high-risk cohort to minimise the risk of hospitalisation readmissions.”